Johannes Schimunek

Johannes Schimunek

Auto-generated profile, based on publicly available information

Johannes Schimunek

Johannes Kepler University

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 November 2023 in Molecular Informatics
Verified
Journal Article
Open access
JSJohannes Schimunek
Johannes Schimunek
PSPhilipp Seidl
Philipp Seidl
KEKatarina Elez
Katarina Elez
THTim Hempel
Tim Hempel
TLTuan Le
Tuan Le
THThomas M. Hermans
Thomas M. Hermans
The COVID‐19 pandemic continues to pose a substantial threat to human lives and is likely to do so for years to come. Despite the availability of vaccines, searching for efficient small‐molecule drugs that are widely available, including in low‐ and middle‐income countries, is an ongoing challenge. In this work, we report the results of an open science community effort, the “Billion molecules against COVID‐19 challenge”, to identify small‐molecule inhibitors against SARS‐CoV‐2 or relevant human receptors. Participating teams used a wide variety of computational methods to screen a minimum of 1 billion virtual molecules against 6 protein targets. Overall, 31 teams participated, and they suggested a total of 639,024 molecules, which were subsequently ranked to find ‘consensus compounds’. The organizing team coordinated with various contract research organizations (CROs) and collaborating institutions to synthesize and test 878 compounds for biological activity against proteases (Nsp5, Nsp3, TMPRSS2), nucleocapsid N, RdRP (only the Nsp12 domain), and (alpha) spike protein S. Overall, 27 compounds with weak inhibition/binding were experimentally identified by binding‐, cleavage‐, and/or viral suppression assays and are presented here. Open science approaches such as the one presented here contribute to the knowledge base of future drug discovery efforts in finding better SARS‐CoV‐2 treatments.

30 April 2025 in Journal of Chemical Information and Modeling
Verified
Journal Article
Open access
JSJohannes Schimunek
Johannes Schimunek
SLSohvi Luukkonen
Sohvi Luukkonen
GKGünter Klambauer
Günter Klambauer
Today’s drug discovery increasingly relies on computational and machine learning approaches to identify novel candidates, yet data scarcity remains a significant challenge. To address this limitation, we present MHNfs, an application specifically designed to predict molecular activity in low-data scenarios. At its core, MHNfs leverages a state-of-the-art few-shot activity prediction model, named MHNfs, which has demonstrated strong performance across a large set of prediction tasks in the benchmark data set FS-Mol. The application features an intuitive interface that enables users to prompt the model for precise activity predictions based on a small number of known active and inactive molecules, akin to interactive interfaces for large language models. To evaluate its efficacy, we simulate real-world scenarios by recasting PubChem bioassays as few-shot prediction tasks. MHNfs offers a streamlined and accessible solution for deploying advanced few-shot learning models, providing a valuable tool for accelerating drug discovery.

7 April 2023 in ChemRxiv
Verified
Preprint
Open access
PDF file
JSJohannes Schimunek
Johannes Schimunek
PSPhilipp Seidl
Philipp Seidl
KEKatarina Elez
Katarina Elez
THTim Hempel
Tim Hempel
TLTuan Le
Tuan Le
THThomas M. Hermans
Thomas M. Hermans
The COVID-19 pandemic continues to pose a substantial threat to human lives and is likely to do so for years to come. Despite the availability of vaccines, searching for efficient small-molecule drugs that are widely available, including in low- and middle-income countries, is an ongoing challenge. In this work, we report the results of a community effort, the “Billion molecules against Covid-19 challenge”, to identify small-molecule inhibitors against SARS-CoV-2 or relevant human receptors. Participating teams used a wide variety of computational methods to screen a minimum of 1 billion virtual molecules against 6 protein targets. Overall, 31 teams participated, and they suggested a total of 639,024 potentially active molecules, which were subsequently ranked to find ‘consensus compounds’. The organizing team coordinated with various contract research organizations (CROs) and collaborating institutions to synthesize and test 878 compounds for activity against proteases (Nsp5, Nsp3, TMPRSS2), nucleocapsid N, RdRP (Nsp12 domain), and (alpha) spike protein S. Overall, 27 potential inhibitors were experimentally confirmed by binding-, cleavage-, and/or viral suppression assays and are presented here. All results are freely available and can be taken further downstream without IP restrictions. Overall, we show the effectiveness of computational techniques, community efforts, and communication across research fields (i.e., protein expression and crystallography, in silico modeling, synthesis and biological assays) to accelerate the early phases of drug discovery.

7 May 2026
Verified
Book Chapter
Closed access
MVMiguel Vázquez
Miguel Vázquez
KIKevin Innerebner
Kevin Innerebner
APAlexander Prock
Alexander Prock
GKGünter Klambauer
Günter Klambauer
ELElisabeth Lex
Elisabeth Lex
APAxel Polleres
Axel Polleres

16 September 2026 in Journal of Chemical Information and Modeling
Verified
Journal Article
Open access
AEAntonia Ebner
Antonia Ebner
CBChristoph Bartmann
Christoph Bartmann
STSonja Topf
Sonja Topf
GKGünTer Klambauer
GünTer Klambauer
JSJohannes Schimunek
Johannes Schimunek
SLSohvi Luukkonen
Sohvi Luukkonen
Deep learning has fundamentally transformed fields such as computer vision and natural language processing since the early 2010s and has strongly influenced biomedical research. For drug discovery specifically, a key inflection point─akin to vision’s “ImageNet moment”─arrived in 2015, when deep neural networks surpassed traditional approaches in the Tox21 Data Challenge. This milestone accelerated the adoption of deep learning methods across the pharmaceutical industry, and today, most major companies have integrated these approaches into their research pipelines. Following the conclusion of the Tox21 Challenge, its data set was incorporated into several established benchmarks, including MoleculeNet and the Open Graph Benchmark. However, during these integrations, the data set was altered, and labels were imputed or manufactured, resulting in a loss of comparability across studies. Consequently, the extent to which bioactivity and toxicity prediction methods have improved over the past decade remains unclear. To this end, we introduce a reproducible leaderboard, hosted on Hugging Face with the original Tox21 Challenge data set, together with a set of baseline and representative methods. The current version of the leaderboard indicates that the original Tox21 winner from 2015─the ensemble-based DeepTox method─and the descriptor-based self-normalizing neural networks introduced in 2017 continue to perform competitively and rank among the top methods for toxicity prediction, raising questions about the extent of progress achieved over the past decade. As part of this work, we provide public access to all baselines and evaluated models for inference via standardized API end points on Hugging Face Spaces.